NASDAQ:SYBX Synlogic (SYBX) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free SYBX Stock Alerts $1.79 +0.01 (+0.56%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$1.70▼$1.8550-Day Range$1.72▼$3.6052-Week Range$1.55▼$10.64Volume43,940 shsAverage Volume53,582 shsMarket Capitalization$20.85 millionP/E RatioN/ADividend YieldN/APrice Target$65.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Synlogic alerts: Email Address Synlogic MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside3,531.3% Upside$65.00 Price TargetShort InterestHealthy0.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.83Based on 11 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.09) to ($3.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 starsMedical Sector751st out of 939 stocksPharmaceutical Preparations Industry356th out of 444 stocks 3.1 Analyst's Opinion Consensus RatingSynlogic has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.00, Synlogic has a forecasted upside of 3,531.3% from its current price of $1.79.Amount of Analyst CoverageSynlogic has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.37% of the float of Synlogic has been sold short.Short Interest Ratio / Days to CoverSynlogic has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Synlogic has recently increased by 9.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSynlogic does not currently pay a dividend.Dividend GrowthSynlogic does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYBX. Previous Next 1.2 News and Social Media Coverage News SentimentSynlogic has a news sentiment score of -0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Synlogic this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for SYBX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat Follows3 people have added Synlogic to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Synlogic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.01% of the stock of Synlogic is held by insiders.Percentage Held by Institutions63.40% of the stock of Synlogic is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Synlogic are expected to decrease in the coming year, from ($2.09) to ($3.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Synlogic is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Synlogic is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSynlogic has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Synlogic Stock (NASDAQ:SYBX)Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.Read More SYBX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYBX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comFY2024 Earnings Estimate for Synlogic, Inc. Issued By Chardan Capital (NASDAQ:SYBX)March 23, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Synlogic, Inc. Cut by Analyst (NASDAQ:SYBX)March 29, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 21, 2024 | markets.businessinsider.comHold Rating on Synlogic Amidst Lead Program Discontinuation and Strategic UncertaintiesMarch 21, 2024 | americanbankingnews.comSynlogic (NASDAQ:SYBX) Rating Increased to Neutral at HC WainwrightMarch 19, 2024 | globenewswire.comSynlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 20, 2024 | finance.yahoo.comSynlogic Adopts Limited Duration Stockholders Rights PlanFebruary 20, 2024 | globenewswire.comSynlogic Adopts Limited Duration Stockholders Rights PlanMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.February 13, 2024 | markets.businessinsider.comHold Rating on Synlogic Amid Discontinued Lead Program and Reduced Price TargetFebruary 9, 2024 | finanznachrichten.deSynlogic, Inc.: Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate UpdateFebruary 9, 2024 | in.investing.comSynlogic plunges as it ceases operations following decision to discontinue Synpheny-3 studyFebruary 9, 2024 | realmoney.thestreet.comSynlogic just downgraded at Chardan, here's whyFebruary 9, 2024 | msn.comRare Disease Focused-Synlogic Pulls Plug On Lead Program, Shares NosediveFebruary 9, 2024 | bizjournals.comSynlogic cuts most workers after halting rare disease drug trialFebruary 9, 2024 | msn.comSynlogic shares crater amid company shut down, failed drug studyFebruary 9, 2024 | msn.comWhy Is Synlogic (SYBX) Stock Down 55% Today?February 9, 2024 | investorplace.comWhy Is Synlogic (SYBX) Stock Down 55% Today?February 8, 2024 | marketwatch.comSynlogic to Cease Operations, Cut Almost All Employees After Ending TrialFebruary 8, 2024 | marketwatch.comSynlogic Shares Tumble 55% on Discontinued Trial, Halt to OperationsFebruary 8, 2024 | msn.comSynlogic to discontinue lead drug program, cease operationsFebruary 8, 2024 | finance.yahoo.comSynlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate UpdateFebruary 8, 2024 | finance.yahoo.comSynlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate UpdateFebruary 6, 2024 | ca.finance.yahoo.comSynlogic Inc (MIN.MU)February 3, 2024 | finanznachrichten.deSynlogic, Inc.: Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaFebruary 2, 2024 | finance.yahoo.comSynlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical HomocystinuriaJanuary 17, 2024 | benzinga.comSynlogic Stock (NASDAQ:SYBX) Dividends: History, Yield and DatesSee More Headlines Receive SYBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Synlogic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SYBX CUSIPN/A CIK1527599 Webwww.synlogictx.com Phone(617) 401-9975Fax512-681-5201Employees6Year Founded2013Price Target and Rating Average Stock Price Target$65.00 High Stock Price Target$90.00 Low Stock Price Target$30.00 Potential Upside/Downside+3,531.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($10.8767) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,280,000.00 Net Margins-1,699.23% Pretax Margin-1,698.84% Return on Equity-109.34% Return on Assets-72.85% Debt Debt-to-Equity RatioN/A Current Ratio2.45 Quick Ratio2.45 Sales & Book Value Annual Sales$3.37 million Price / Sales6.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book0.39Miscellaneous Outstanding Shares11,650,000Free Float10,714,000Market Cap$20.85 million OptionableOptionable Beta1.09 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Antoine Awad (Age 43)Principal Executive Officer & COO Comp: $566.55kDr. Timothy K. Lu M.D. (Age 43)Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. James J. Collins Ph.D. (Age 57)Co-Founder & Member of Scientific Advisory Board Ms. Mary Beth Dooley (Age 43)Head of Finance and Principal Financial Officer & Principal Accounting Officer Mr. Brendan St. AmantGeneral Counsel & Corporate SecretaryMr. Ajay MunshiVice President of Corporate DevelopmentMr. Adam J. ThomasChief People OfficerDr. Caroline B. Kurtz Ph.D.Chief Development OfficerMs. Molly Harper (Age 47)Chief Business Officer Dr. Neal Sondheimer M.D.Ph.D., VP & Head of ClinicalMore ExecutivesKey CompetitorsTRACON PharmaceuticalsNASDAQ:TCONPieris PharmaceuticalsNASDAQ:PIRSMinerva NeurosciencesNASDAQ:NERVNeurAxisNASDAQ:NRXSPurple BiotechNASDAQ:PPBTView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 38,862 shares on 3/11/2024Ownership: 2.050%Vanguard Group Inc.Bought 38,862 shares on 2/15/2024Ownership: 2.050%Citadel Advisors LLCBought 10,860 shares on 2/15/2024Ownership: 0.118%Armistice Capital LLCBought 455,126 shares on 2/13/2024Ownership: 11.480%Harbor Capital Advisors Inc.Bought 9,282 shares on 1/8/2024Ownership: 0.334%View All Insider TransactionsView All Institutional Transactions SYBX Stock Analysis - Frequently Asked Questions Should I buy or sell Synlogic stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synlogic in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SYBX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYBX, but not buy additional shares or sell existing shares. View SYBX analyst ratings or view top-rated stocks. What is Synlogic's stock price target for 2024? 5 brokerages have issued 12-month price targets for Synlogic's stock. Their SYBX share price targets range from $30.00 to $90.00. On average, they anticipate the company's stock price to reach $65.00 in the next year. This suggests a possible upside of 3,531.3% from the stock's current price. View analysts price targets for SYBX or view top-rated stocks among Wall Street analysts. How have SYBX shares performed in 2024? Synlogic's stock was trading at $3.85 at the start of the year. Since then, SYBX stock has decreased by 53.5% and is now trading at $1.79. View the best growth stocks for 2024 here. When is Synlogic's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SYBX earnings forecast. How were Synlogic's earnings last quarter? Synlogic, Inc. (NASDAQ:SYBX) announced its quarterly earnings data on Tuesday, March, 19th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($1.11) by $0.60. The biotechnology company had revenue of $2.77 million for the quarter, compared to analyst estimates of $2.71 million. Synlogic had a negative net margin of 1,699.23% and a negative trailing twelve-month return on equity of 109.34%. When did Synlogic's stock split? Synlogic's stock reverse split before market open on Thursday, September 28th 2023. The 1-15 reverse split was announced on Thursday, September 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Synlogic own? Based on aggregate information from My MarketBeat watchlists, some companies that other Synlogic investors own include Reata Pharmaceuticals (RETA), Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL) and Verastem (VSTM). Who are Synlogic's major shareholders? Synlogic's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (11.48%), Vanguard Group Inc. (2.05%), Vanguard Group Inc. (2.05%), Harbor Capital Advisors Inc. (0.33%), Citadel Advisors LLC (0.12%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Antoine Awad, Aoife Brennan and Michael Vangsted Jensen. View institutional ownership trends. How do I buy shares of Synlogic? Shares of SYBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYBX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.